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Background Materials & Methods
57 patients were included in the principal trial. 39 of them, with trough levels measured 
Figure1: Genotyping vs. endoxifen level and endoxifen/N-D-tamoxifen ratioStatistical considerations Results
Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early
and advanced stage breast cancer in women and men. It is a pro-drug having
weak affinity with the estrogen receptor and needs to be converted to its main
metabolite, endoxifen (endox), to have full anticancer activity.
C h 2D6 (CYP2D6) l j l i h b li f if
> 12 h post-dose, were eligible for these analyzes.
7 patients were treated with CYP2D6 inhibitors (3 citalopram, 1 escitalopram, 1 
venlafaxine, 1 risperidone, 1 paroxetine).
Study design:
Tamoxifen and metabolitesTamoxifen 20 mg/day
≥ 4 months
Table 1: Patients characteristics
A M di ( ) 52 (32 78)ytoc rome p ays a ma or ro e n t e meta o sm o tamox en
to endoxifen. It is genetically highly polymorphic and its activity influences
profoundly the synthesis of endoxifen and potentially the efficacy of tamoxifen
treatment.
G t i i tl th t id l d h i t di d l i
Inclusion
Bl d li 2 5 L i EDTA t b
CYP2D6 genotyping
CYP2D6 and CYP3A4/5 phenotyping
ge e an range  years  -
Race Caucasian
African
Indian
37
1
1
Premenopausal
Postmenopausal
27
12
T hi t l D t l i i 25
# #
eno yp ng s curren y e mos w e y use approac n s u es an a so n
clinical practice to categorize patients as poor- (PM), intermediate- (IM),
extensive- (EM) and ultra rapid-metabolizers (UM). Some clinicians already
use genotyping in order to tailor the endocrine therapy of their patients.
Owing to the large inter individual variations in concentrations of the active
oo samp ng: x m n u es
Samples were centrifuged without delay: cellular pellet was used for genetics analyses and
plasma for determination of levels of tamoxifen and its metabolites by LC tandem MS; and
stored frozen (-80°C).
The analyses were done centrally in our laboratories:
¾Tamoxifen and Metabolites levels in plasma Table 2: Plasma levels of tamoxifen and its metabolites:
umor s o ogy uc a nvas ve
Lobular invasive
Other invasive subtypes
Ductal in situ
8
5
1
Treatment adherence > 95%
Figure 2: linear regression phenotype vs. endoxifen level and endoxifen/N-D-tamoxifen ratio
-
moitey due to genetic and non-genetic influences renders the predictive value
of the test uncertain for an individual patient. A significant number of patients
classified as EM or IM by genotyping have indeed relatively low endoxifen
levels similar to PMs1. This suggests that genotyping is probably not the
ti l th d f di ti d if l l
An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
method was used for the simultaneous measurements of tamoxifen and its metabolites2.
¾CYP2D6 genotyping analyses
alleles *3, *4, *5, *6, *XN
¾CYP2D6 phenotyping test
The dextromethorphan test was used for the determination of CYP2D63
Geometric 
mean (nM) CV (%)
Median
(nM)
Range
(nM)
Tam 372 44 351 187-1070
N-D-Tam 804 42 729 383-1779
4 OH Tam 5 8 50 5 8 2 6 18 8
Conclusions
op ma me o or pre c ng en ox en eve s. ,.
¾CYP3A4/5 phenotyping test
midazolam metabolic ratio4 was used for the determination of CYP3A4 activity.
Eligibility criteria
- - . . . - .
Endoxifen 63.3 84 72.2 14.1-302
Table  3: How do CYP2D6 genotype or phenotype and CYP3A4/5 phenotype influence 
concentrations of tamoxifen and its metabolites (linear regression analyses):
Correlation to CYP2D6 genotype:
# 0: PM (n=2); 1: IM (n=10); 2: EM (n=26); 3: UM (n=1); empty figures = patients with CYP2D6 inhibitors; filled 
figures = patients without CYP2D6 inhibitors
Tamoxifen and its main metabolites Factors influencing endoxifen level 
 Our data confirm a significant correlation between plasma levels of 
endoxifen and CYP2D6 activity defined by genotyping or by phenotyping.
 Following the multivariate analyses, phenotyping appears slightly 
superior to genotyping in the prediction of endoxifen’s level
–Signed informed consent.
–Breast cancer patients treated with tamoxifen for ≥ 4 months
– No history of deep venous thrombosis or pulmonary embolism.
– No history of endometrial carcinoma.
– No known history of vaginal bleeding, endometriosis, endometrial hyperplasia, endometrial
hypertrophy and/or polyps.
Tam N-D-Tam 4-OH-
Tam
Endox Endox/N-
D-Tam
4-OH-
Tam/Tam
N-D-
Tam/Tam
R2 (%) 6 12 16 33 47 50 3
P 0.13 0.027 0.012 0.0001 <0.0001 <0.0001 0.27
C l ti t CYP2D6 h t (d t th h /d t h ti )
METHODS OF 
ANALYZE
        .
 Due to the large overlap between EM and IM, the predictive value of 
genotyping seems uncertain for an individual patient.
 Our results are consistent with a potential superiority of monitoring the 
active metabolites themselves rather than genetic or phenotypic
– No pregnancy nor lactating women.
– No known allergy to midazolam or dextromethorphan
Treatment adherence assessment
Each patient completed an anonymized questionnaire to report semi-quantitatively her treatment
adherence.
orre a on o p eno ype ex rome orp an ex rorp an ra o :
Tam N-D-Tam
4-OH-
Tam Endox
Endox/N-
D-Tam
4-OH-
Tam/Tam
N-D-
Tam/Tam
R2 (%) 2 8 8 39 55 26 6
P 0.35 0.08 0.1 <0.0001 <0.0001 0.0013 0.13
Objective
        
surrogates 
 These conclusions are based on a limited number of patients. The 
study assessing tamoxifen metabolism and the impact of  tamoxifen 
dose on endoxifen level is ongoing.To assess if the correlation between genotyping and endoxifen levels is strong
enough to use this test in individual patients and what is the value of CYP2D6
Statistical considerations
The CYP2D6 genotypes were categorized into four groups and scored on the basis of the
number of functional alleles (PM = homozygous loss of functional allele, IM = heterozygous loss
of functional allele, EM = homozygous reference allele, UM= multiple functional alleles).
Correlations between log-transformed trough levels of tamoxifen its metabolites and the ratios
Correlation to CYP3A4/5 phenotype (1’-OH-midazolam/midazolam ratio) :
Tam N-D-Tam 4-OH-
Tam
Endox Endox/N-
D-Tam
4-OH-
Tam/Tam
N-D-
Tam/Tam
R2 (%) 36 12 23 12 1 1 31
P 0.0001 0.036 0.003 0.034 0.51 0.56 0.0003
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and CYP3A4/5 phenotyping?
We present here a substudy of a larger ongoing trial studying tamoxifen
metabolism in breast cancer patients (NCT00963209).
, ,
endoxifen/N-desmethyltamoxifen, N-desmethyltamoxifen/tamoxifen with CYP2D6 genotypes,
phenyotypes and CYP3A4/5 phenotypes were analyzed by univariate and multivariate linear
regression analyses and analyses of variance. Comparison between models were performed
based the adjusted R2 and the likelihood ratio test, at a significance level of p=0.05. All data
analyses were conducted with Stata statistical software (StataCorp. 2009. Stata Statistical
Software: Release 11 College Station TX: StataCorp LP)
Multivariate analyses
Performed to assess the correlation between endoxifen level and the independent variables
(CYP2D6 genotype and phenotype and CYP3A4/5 phenotype):
• Only CYP2D6 and CYP3A4/5 phenotypes influenced significantly endoxifen level.
• Suggests no additional statistical predictive value of CYP2D6 genotype in addition to CYP2D6
phenotype on endoxifen (p = 0.36) and endoxifen/N-D-Tam ratio (p = 0.17).
Pharmacogenomics J 2009;9:34-41.
4. Eap et al., E J Clin Pharmacol 60 (2004) 237 – 246
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• An additional effect of CYP3A4 phenotype was observed, increasing the predictive value of
endoxifen levels (p < 0.0001, adjusted R2 = 50%).
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